Lilly strikes again, buying Calytrix in $1.5bn deal

News

Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5 billion.

If it goes through, the deal will give Lilly rights to privately held Calytrix's lead drug for essential thrombocythaemia (ET) and myelofibrosis (MF) – two forms of myeloproliferative neoplasm (MPN) – which is still in preclinical development.

Founded in 2025 by JP Morgan Life Sciences Private Capital, Wellesley Hills, Massachusetts-based Calytrix has been built around a 'biparatopic' antibody platform – in other words, antibodies that can bind to two separate sites on the same target protein.

Its lead candidate targets mutant calreticulin (mCALR), which is expressed on the surface of abnormal cells in ET and MF and drives cancer progression by activating uncontrolled cell growth. mCALR is found in roughly 25% to 30% of primary myelofibrosis cases and 20% to 30% of ET cases, making it the second most common oncogenic driver after JAK2 mutations.

According to Calytrix, mCALR is a tumour-specific cell-surface target with the potential to deplete disease-driving mutant cells, while sparing normal tissues and preserving healthy bone marrow function. That differentiates it from current therapies for ET and MF, which "primarily manage symptoms and complications," said the company.

Lilly is a player in the blood cancer category with drugs like Jaypirca (pirtobrutinib), a BTK inhibitor used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL), which is on track to achieve sales of around $850 million this year.

"From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF," said Brad Prosek, the biotech's president and chief executive. "This transaction represents an important step toward accelerating that vision."

Under the terms of the agreement, Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and clinical and regulatory milestones.

Lilly has been spending freely on M&A and other business development deals in the last few quarters, with the additions to its pipeline fuelled by cash generated by its fast-growing tirzepatide-based therapies – Mounjaro and Zepbound – for type 2 diabetes and obesity.

The new acquisition is thought to take Lilly's tally to more than a dozen worth tens of billions of dollars since the start of the year, coming a few months after it agreed to buy immunology and inflammation specialist Merida Biosciences for up to $2.88 billion and psychedelics developer AtaiBeckley for up to $3.8 billion in the summer.